The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
- Equal contributors
1 Department of Medical Oncology, Department of Oncology, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China
2 Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
3 Department of Nuclear Medicine, Department of Oncology, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China
4 Department of Medical Oncology, Fudan University Shanghai Cancer Center Minhang Branch, Fudan University, Shanghai, China
Citation and License
BMC Cancer 2013, 13:42 doi:10.1186/1471-2407-13-42Published: 31 January 2013
Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated.
305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up.
In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.
SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype.